A Controlled Trial of a Human Papillomavirus Type 16 Vaccine

20021,607 citationsJournal Articlebronze Open Access

Authors

Laura A. Koutsky · University of Washington

Kevin A. Ault

Cosette M. Wheeler

Darron R. Brown

Eliav Barr · Merck & Co., Inc., Rahway, NJ, USA (United States)

Frances B. Alvarez · Merck & Co., Inc., Rahway, NJ, USA (United States)

Lisa M. Chiacchierini · Merck & Co., Inc., Rahway, NJ, USA (United States)

Kathrin U. Jansen · Merck (Singapore)

Abstract

Administration of this HPV-16 vaccine reduced the incidence of both HPV-16 infection and HPV-16-related cervical intraepithelial neoplasia. Immunizing HPV-16-negative women may eventually reduce the incidence of cervical cancer.

Topics & Keywords

Cervical Cancer and HPV Research Immunotherapy and Immune Responses Hepatitis B Virus Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 347, Issue 21, pp. 1645-1651

DOI: 10.1056/nejmoa020586

Field-Weighted Citation Impact: 106.66